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ABSTRACT
Introduction: The careHPV™ Test is a US FDA approved, CE mark, and WHO prequalified in vitro diagnostic test 
designed to screen for 14 high-risk human papillomavirus (HRHPV) genotypes. The careHPV™ Test is one of the 
commercial HPV test validated to be used in low resource settings, boasting the economy of processing a maximum 
of 90 samples per batch and a near point-of-care turnaround time of 3 hours. According to the manufacturer, cer-
vical swabs stored in careHPV™ Collection Medium are stable for 30 days when stored between 2-8°C. However, 
we often had difficulty consolidating enough samples for a full batch-test within 30 days, especially when screening 
women living in the low-density villages in rural Sarawak, Malaysian Borneo. This study aimed to evaluate the sta-
bility and repeatability of cervical swabs preserved in careHPV™ Collection Medium stored at 4°C exceeding the 
recommended 30 days using the careHPV™ Test. Methods: Two groups of confirmed HRHPV-positive and HRH-
PV-negative cervical swab samples in careHPV™ Collection Medium consisting of 4 samples each were maintained 
at 4°C and tested using the careHPV™ Test at Day -38, -123, -131, -223, and -395. Results: All cervical swabs in the 
careHPV™ Collection Medium stored at 4°C remained stable for testing and demonstrated 100% repeatability for at 
least 395 days from the day of collection. Conclusion: The careHPV™ Test can be successfully performed on cervical 
swabs preserved in careHPV™ Collection Medium, which were stored at 4°C for at least 395 days. 
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Cervical cancer is the fourth most frequently diagnosed 
cancer and the fourth leading cause of cancer death 
in women worldwide. Cervical cancer is responsible 
for approximately 570,000 cases and 311,000 deaths 
annually (1). It was estimated that more than 80% 
of cervical cancer incidences were from low and 
medium-income countries (LMICs) that lack organised 
screening and human papillomavirus (HPV) vaccination 
programmes(2). There is also a significant disparity 
between the urban and rural populations(3,4), mainly 
due to the inequitable access to proper healthcare 
facilities, poverty, and other cofactors (5).
Human papillomavirus (HPV) is the primary factor in 
the development of cervical cancer (6). Currently, more 
than 200 HPV genotypes have been identified with 
approximately 40 genotypes are sexually transmitted, 
and 14 of them are oncogenic and referred to as 
high-risk HPV (HR-HPV) (7). Since oncogenesis from 
infection to the development of precancerous lesions 
and cancer is a long and complicated process, this opens 
up a window of opportunity for prevention, diagnosis, 
and treatment (8). Early cervical cancer screening 
combined with HPV vaccination will effectively reduce 
cervical cancer incidence, as demonstrated in many 
developed countries (1). Cervical cancer screening 
using the conventional Papanicolaou (Pap) smear 
was initiated in Malaysia in 1969, with an annual 
cost of approximately RM3.55 million (approximately 
USD800,000) in 2003 (9). Despite the investment, 
the national Pap smear coverage was only 23% in 
2002 and 22% in 2012, far from the recommended 
coverage of 80% by the World Health Organisation 
(WHO)(10). Pap smears have a very high specificity 
of 98-99%, but their sensitivity is generally accepted 
as 50% (11). A successful Pap smear programme with 
trained healthcare professionals, including smear takers, 
cytotechnologists, cytopathologists, colposcopists, 
and programme managers, could achieve a sensitivity 
of 75% (11). Nonetheless, a cross-sectional study in 
2013 involving 316 eligible women in West Malaysia 
